Biogen Sees At Least Six Tecfidera Generics And 90% Discounts
Pace Of Erosion ‘Difficult To Predict’
Biogen counted the cost of losing its monopoly on Tecfidera in the third quarter, with multiple generic entrants rushing in to the multi-billion-dollar opportunity.
